First results from FORT study for PKAN

from | August 23, 2019

The pharmaceutical company Retrophin had developed the drug fosmetpantotenate for the treatment of PKAN. This was tested for safety and efficacy as part of a placebo-controlled and multicenter double-blind clinical trial (FORT trial). This study was completed in July. An extension study, in which all study participants receive the drug, has not yet been completed.

On August 22, Retrophin presented the first results from the FORT study at a Press release (in English).

Prof. Dr. Thomas Klopstock, medical director of the study, has developed a Statement published.

It is disappointing for all PKAN patients and their families that the study was not able to produce clearly positive results as hoped. However, detailed analyses are still pending.

Subscribe to our Hoffnungsbaum newsletter!

With our newsletter e-mails you will receive valuable information about NBIA. If you would like to receive additional information on individual NBIA variants or special information for researchers/clinicians in addition to the general newsletter, please click here: Subscribe to additional information

Privacy policy

You have successfully registered!